Open | - |
Close | - |
Volume / Avg. | 0 / 652.246K |
Day Range | - - - |
52 Wk Range | 0.600 - 1.710 |
Market Cap | $117.078M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 51 |
Short Interest | 7.89% |
Days to Cover | 16.06 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Citius Pharma (NASDAQ: CTXR) through any online brokerage.
Other companies in Citius Pharma’s space includes: Rani Therapeutics Hldgs (NASDAQ:RANI), Telomir Pharmaceuticals (NASDAQ:TELO), Trevi Therapeutics (NASDAQ:TRVI), Cormedix (NASDAQ:CRMD) and Milestone Pharmaceuticals (NASDAQ:MIST).
The latest price target for Citius Pharma (NASDAQ: CTXR) was reported by HC Wainwright & Co. on Wednesday, February 14, 2024. The analyst firm set a price target for 4.00 expecting CTXR to rise to within 12 months (a possible 443.55% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Citius Pharma (NASDAQ: CTXR) is $0.7359 last updated March 18, 2024 at 7:40 PM EDT.
There are no upcoming dividends for Citius Pharma.
Citius Pharma’s Q2 earnings are confirmed for Friday, May 10, 2024.
There is no upcoming split for Citius Pharma.
Citius Pharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.